New 24-week data revealed that povorcitinib (INCB54707), an oral JAK1 inhibitor, continues to result in improvements for adults with moderate to severe hidradenitis suppurativa (HS), according to results from two phase 3 trials that were presented at the 2025 European Association of Dermatology and Venereology (EADV) Congress.

These findings support earlier results from the STOP-HS1 and STOP-HS2 trials, which will be useful for approval in Europe in 2025 and in the U.S. in early 2026. Incyte, the drug’s manufacturer, said in a press release that the results provide strong support for povorcitinib as a potential new treatment option for a condition with limited therapies.

HS is a chronic inflammatory skin condition that causes painful nodules and abscesses in areas where skin rubs togethe

See Full Page